SANDOZ Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANDOZ, and what generic alternatives to SANDOZ drugs are available?
SANDOZ has four hundred and eighty-nine approved drugs.
There are nine US patents protecting SANDOZ drugs. There are thirty-three tentative approvals on SANDOZ drugs.
There are one hundred and three patent family members on SANDOZ drugs in thirty-four countries and five hundred and three supplementary protection certificates in seventeen countries.
Summary for SANDOZ
International Patents: | 103 |
US Patents: | 9 |
Tradenames: | 322 |
Ingredients: | 300 |
NDAs: | 489 |
Patent Litigation for SANDOZ: | See patent lawsuits for SANDOZ |
PTAB Cases with SANDOZ as petitioner: | See PTAB cases with SANDOZ as petitioner |
Drugs and US Patents for SANDOZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | PROPRANOLOL HYDROCHLORIDE | propranolol hydrochloride | TABLET;ORAL | 072197-001 | Jul 5, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sandoz | BICALUTAMIDE | bicalutamide | TABLET;ORAL | 078575-001 | Jul 6, 2009 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sandoz | CLARITHROMYCIN | clarithromycin | FOR SUSPENSION;ORAL | 065283-002 | Sep 4, 2007 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sandoz | FLUDARABINE PHOSPHATE | fludarabine phosphate | INJECTABLE;INJECTION | 022137-001 | Sep 21, 2007 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sandoz | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 217150-001 | Sep 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SANDOZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sandoz | EXELON | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 022083-001 | Jul 6, 2007 | 5,602,176 | ⤷ Try a Trial |
Sandoz | CILOXAN | ciprofloxacin hydrochloride | OINTMENT;OPHTHALMIC | 020369-001 | Mar 30, 1998 | 4,670,444*PED | ⤷ Try a Trial |
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | 5,837,284 | ⤷ Try a Trial |
Sandoz | FOCALIN XR | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021802-005 | Oct 23, 2009 | 6,635,284 | ⤷ Try a Trial |
Sandoz | LOTREL | amlodipine besylate; benazepril hydrochloride | CAPSULE;ORAL | 020364-004 | Mar 3, 1995 | 6,162,802 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANDOZ drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 1.5 mg, 3 mg, 4.5 mg and 6 mg | ➤ Subscribe | 2004-04-21 |
➤ Subscribe | Transdermal System Extended-release | 13.3 mg/24 hr | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | Extended-release Capsules | 15 mg | ➤ Subscribe | 2007-05-14 |
➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Extended-release Capsule | 30 mg | ➤ Subscribe | 2010-12-15 |
➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2009-02-19 |
➤ Subscribe | Extended-release capsules | 25 mg | ➤ Subscribe | 2011-09-30 |
➤ Subscribe | Extended-release Tablets | 80 mg | ➤ Subscribe | 2007-03-15 |
➤ Subscribe | Extended-release Capsules | 10 mg | ➤ Subscribe | 2007-05-21 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2004-05-27 |
➤ Subscribe | Capsules | 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg | ➤ Subscribe | 2004-06-09 |
➤ Subscribe | Ophthalmic Emulsion | 0.05% | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Oral Solution | 2 mg/mL | ➤ Subscribe | 2004-11-05 |
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Oral Solution | 4 mg/5 mL | ➤ Subscribe | 2004-12-20 |
➤ Subscribe | Extended-release Capsules | 5mg, 10mg and 20 mg | ➤ Subscribe | 2007-03-30 |
➤ Subscribe | Injection | 0.05 mg/mL, 100 mL vial | ➤ Subscribe | 2008-08-29 |
➤ Subscribe | Extended-release Capsule | 40 mg | ➤ Subscribe | 2010-12-20 |
➤ Subscribe | Otic Suspension | 0.3%/0.1% | ➤ Subscribe | 2012-07-31 |
➤ Subscribe | Extended-release capsules | 35 mg | ➤ Subscribe | 2011-09-29 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2004-07-27 |
➤ Subscribe | Extended-release Capsules | 20 mg, 30 mg and 40 mg | ➤ Subscribe | 2006-08-21 |
➤ Subscribe | Capsules | 5 mg/40 mg and 10 mg/40 mg | ➤ Subscribe | 2006-11-17 |
International Patents for SANDOZ Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Poland | 212457 | ⤷ Try a Trial |
Brazil | PI0717093 | ⤷ Try a Trial |
China | 101522171 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008042619 | ⤷ Try a Trial |
Malaysia | 141763 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SANDOZ Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2782584 | LUC00245 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
1602370 | SPC/GB09/024 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4 |
0193926 | C980031 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512 |
1746976 | 300885 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IRINOTECANSUCROSOFAATZOUT; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
2236132 | 122015000006 | Germany | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.